Packaging systems for human recombinant adenovirus to be used in gene therapy
Patent 5994128 Issued on November 30, 1999. Estimated Expiration Date: 
March 25, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 25, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesVitro headful packaging system for cloning DNA fragments as large as 95kb Process for amplifying a target polynucleotide sequence using a single primer-promoter complex Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism Adenovirus vector for gene therapy Adenovirus vectors for gene therapy Helper-free stocks of recombinant adeno-associated virus vectors Patent #: 5753500 InventorsAssigneeApplicationNo. 793170 filed on 03/25/1997US Classes:435/325, ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE424/93.21, Eukaryotic cell435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)435/455, Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cell536/23.1DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)ExaminersPrimary: Campell, Bruce R.Assistant: Nguyen, Hiep T. Attorney, Agent or FirmForeign Patent References
International ClassC12N 015/00Foreign Application Priority Data1995-06-15 EPAbstractPresented are ways to address the problem of replication competent adenovirus in adenoviral production for use with, for example, gene therapy. Packaging cells having no overlapping sequences with a selected vector and are suited for large scale production of recombinant adenoviruses. A system for use with the invention produces adenovirus incapable of replicating. The system includes a primary cell containing a nucleic acid based on or derived from adenovirus and an isolated recombinant nucleic acid molecule for transfer into the primary cell. The isolated recombinant nucleic acid molecule is based on or derived from an adenovirus, and further has at least one functional encapsidating signal, and at least one functional Inverted Terminal Repeat. The isolated recombinant nucleic acid molecule lacks overlapping sequences with the nucleic acid of the cell. Otherwise, the overlapping sequences would enable homologous recombination leading to replication competent adenovirus in the primary cell into which the isolated recombinant nucleic acid molecule is to be transferred.Other References
Field of SearchVECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFORE Recombinant DNA technique included in method of making a protein or polypeptide Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cell Polynucleotide (e.g., RNA, DNA, etc.) Eukaryotic cell DNA or RNA fragments or modified forms thereof (e.g., genes, etc.) |
| ||||||||||||||
